Abstract
In 8 patients with a temporary pacemaker, investigations were carried out into the supranormal phase of excitability induced by Bunaftine, a derivative of ethylenediamine, which has anti-arrhythmic properties. During continuous electrocardiographic recording, and after assessment of the threshold of myocardial stimulation, the supranormal phase was shown by the occasional depolarising effect of subliminal stimulation. By examining the chronological relationship between effective subliminal stimulation and spontaneous rhythm complexes, it was possible to calculate the beginning, end and the duration of the supranormal phase. The Q-T interval, the QRS interval and cardiac frequency were also calculated. The most important factor in this investigation was the decrease, by an average of 57.3 % of the duration of the supranormal phase (p <0.001) after Bunaftine treatment. At the same time, there was found to be a lengthening of the Q-T interval by 11.8 % (p <0,001). The drug does not cause any significant changes in either the length of the QRS interval or cardiac frequency. It is therefore possible that the effect of Bunaftine on the supranormal phase is one way in which it exercises its antiarrhythmic effect.
| Original language | French |
|---|---|
| Pages (from-to) | 141-147 |
| Number of pages | 7 |
| Journal | Annales de Cardiologie et d'Angeiologie |
| Volume | 26 |
| Issue number | 2 |
| Publication status | Published - 1977 |
Fingerprint
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
ACTION DE LA BUNAFTINE SUR LA PHASE SUPERNORMALE DE L'EXCITABILITE MYOCARDIQUE. / Critelli, G.; Rengo, F.; Adinolfi, L.; Santinelli, V.; Ferro, G.; Perticone, F.; Condorelli, M.
In: Annales de Cardiologie et d'Angeiologie, Vol. 26, No. 2, 1977, p. 141-147.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - ACTION DE LA BUNAFTINE SUR LA PHASE SUPERNORMALE DE L'EXCITABILITE MYOCARDIQUE
AU - Critelli, G.
AU - Rengo, F.
AU - Adinolfi, L.
AU - Santinelli, V.
AU - Ferro, G.
AU - Perticone, F.
AU - Condorelli, M.
PY - 1977
Y1 - 1977
N2 - In 8 patients with a temporary pacemaker, investigations were carried out into the supranormal phase of excitability induced by Bunaftine, a derivative of ethylenediamine, which has anti-arrhythmic properties. During continuous electrocardiographic recording, and after assessment of the threshold of myocardial stimulation, the supranormal phase was shown by the occasional depolarising effect of subliminal stimulation. By examining the chronological relationship between effective subliminal stimulation and spontaneous rhythm complexes, it was possible to calculate the beginning, end and the duration of the supranormal phase. The Q-T interval, the QRS interval and cardiac frequency were also calculated. The most important factor in this investigation was the decrease, by an average of 57.3 % of the duration of the supranormal phase (p <0.001) after Bunaftine treatment. At the same time, there was found to be a lengthening of the Q-T interval by 11.8 % (p <0,001). The drug does not cause any significant changes in either the length of the QRS interval or cardiac frequency. It is therefore possible that the effect of Bunaftine on the supranormal phase is one way in which it exercises its antiarrhythmic effect.
AB - In 8 patients with a temporary pacemaker, investigations were carried out into the supranormal phase of excitability induced by Bunaftine, a derivative of ethylenediamine, which has anti-arrhythmic properties. During continuous electrocardiographic recording, and after assessment of the threshold of myocardial stimulation, the supranormal phase was shown by the occasional depolarising effect of subliminal stimulation. By examining the chronological relationship between effective subliminal stimulation and spontaneous rhythm complexes, it was possible to calculate the beginning, end and the duration of the supranormal phase. The Q-T interval, the QRS interval and cardiac frequency were also calculated. The most important factor in this investigation was the decrease, by an average of 57.3 % of the duration of the supranormal phase (p <0.001) after Bunaftine treatment. At the same time, there was found to be a lengthening of the Q-T interval by 11.8 % (p <0,001). The drug does not cause any significant changes in either the length of the QRS interval or cardiac frequency. It is therefore possible that the effect of Bunaftine on the supranormal phase is one way in which it exercises its antiarrhythmic effect.
UR - http://www.scopus.com/inward/record.url?scp=0017353548&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017353548&partnerID=8YFLogxK
M3 - Articolo
VL - 26
SP - 141
EP - 147
JO - Annales de Cardiologie et d'Angeiologie
JF - Annales de Cardiologie et d'Angeiologie
SN - 0003-3928
IS - 2
ER -